What We Do
Harness the specificity of CRISPR to refine your NGS library with CRISPRclean®
The ability to sequence millions of reads from genomes and transcriptomes has yielded an unprecedented discovery on genes and genetic variation. Unfortunately, much of these reads are wasted on over abundant sequences that are captured repeatedly.
Future discovery may be accelerated by cutting through the noise of over abundant sequences. Shifting focus away from abundant genes and increasing sensitivity by lowering background noise is required to enable this discovery. It’s why we created CRISPRclean.
CRISPRclean technology harnesses the specificity of CRISPR-Cas9 to degrade abundant, uninformative sequences in next-generation sequencing (NGS) libraries. With CRISPRclean, you can see more lower expressing transcripts and shift your sequencing power for deeper coverage and improved signal.
Now you can see exactly what you want, breaking through the clutter—and breaking new ground.
Benefits of CRISPRclean technology
Simple automatable workflow
How CRISPRclean works
CRISPRclean mediated depletion can be integrated directly into NGS library prep protocols at various points depending on the application. CRISPR-Cas9 complexes are formed with a pool of designed guide RNAs. After targeted sequences are cut, they cannot be a substrate for PCR amplification or subsequent sequencing. The output is a refined, sequence ready NGS library.
CRISPRclean technology is both specific and highly programmable to remove unwanted sequences for many applications.
View the applications below to learn how Jumpcode is driving discovery today.
Single Cell Analysis
Gain a deeper view of expression profiles of individual cells
Characterize microbial populations and their impact on human health
Infectious Disease Surveillance
Detect known and novel pathogens to accelerate outbreak investigations
Whole Transcriptome Profiling
Measure gene and transcript activity to interrogate gene expression patterns
Customer Story – ImYoo
Isolating informative RNA gives ImYoo™ greater power to grow their business.
ImYoo is a single-cell transcriptomics startup that helps biopharma companies stratify study participants to optimize clinical trials. The company is using single-cell gene expression profiling to understand immune variability and personalize information.
For the US patent, the patent number is US 10,604,802 entitled Genome Fractioning. The patent publication is available here.
For the EP patent, the patent number is EP3102722 entitled Genome Fractioning. The patent publication is available here.